Experts question Covaxin’s high private market price as R&D was govt subsidised

Experts have questioned the rationale of high prices of Covaxin since it is based on an established technology, is domestically-produced, and it’s R&D has been part-subsidised by the Centre. Other vaccines like polio and hepatitis B using a similar technology platform, are affordable due to large volumes and economies of scale, a strategy which should have been followed early-on in the case of Covaxin, they said.

source https://timesofindia.indiatimes.com/india/experts-question-covaxins-high-private-market-price-as-rd-was-govt-subsidised/articleshow/83450863.cms